Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT03886012
Other study ID # OLith10401
Secondary ID
Status Suspended
Phase N/A
First received
Last updated
Start date April 26, 2019
Est. completion date December 30, 2021

Study information

Verified date April 2021
Source Otolith Labs
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Vertigo is among the most common symptoms associated with migraine and affects 26.5% of migraine sufferers, leading to a dramatic impact in life limiting even the most simple activities. A new device, the OtoBand, a transcranial vibrating system, has been shown to mitigate and sometimes prevent vertigo and nausea in healthy subjects. The current study aims to determine if the Otoband can treat or reduce symptoms of Migraine Associated Vertigo (MAV).


Description:

Vertigo is among the most common symptoms associated with migraine and affects 26.5% of migraine sufferers. Migraine Associated Vertigo (MAV) has a dramatic impact on daily life, impacting work, relationships, and even activities of daily living. At the current time, the mainstay of therapy for migraine is pharmaceutical intervention, either acute (particularly triptans, 2) or preventative. However, this therapy has a delayed effect and can lead to a host of side effects. In this project we examine a device that has shown promise and might be beneficial for treating or improving the course of recovery from MAV. The Otoband is a transcranial vibrating system to be placed against the skull, preferably over the mastoid bone, behind the ear. To date, the device has only been systematically tested on healthy volunteers and has shown improvement of vertigo symptoms during the use of virtual reality systems and road motion sickness. Individuals identified at Jefferson University medical center with a history of MAV attacks will be referred to the Otolaryngology Department where their diagnosis will be confirmed and offered to enroll in the study. Participants will be able to take home an Otoband to wear when they have MAV attacks. The Otoband will be set at the effective power (proved to reduce vertigo symptoms in previous studies) and low power (proved to not impact vertigo symptoms, considered as sham device). Participants will have to assay their vertigo symptoms before, during and immediately after wearing the Otoband to evaluate the efficacy of the device.


Recruitment information / eligibility

Status Suspended
Enrollment 40
Est. completion date December 30, 2021
Est. primary completion date December 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: Subject between the ages of 18-65 with a history of frequent Migraine Associated Vertigo (MAV) attacks as characterized by the following: - An episode with acute onset vertigo that lasted at least 15 minutes within the previous 30 days. - At least 5 such episodes in the past 12 months. Exclusion Criteria: 1. History of head injury within the last six months or currently suffering the effects of a head injury 2. Presence of severe aphasia 3. History of diagnosed neuropsychiatric disorders (e.g. hypochondriasis, major depression, schizophrenia) 4. Documented neurodegenerative disorders 5. Pregnancy [Female candidates will be asked if they are pregnant] 6. Prior disorders of hearing and balance including: 1. Ménière's disease 2. Multiple sclerosis 3. Vestibular neuritis 4. Vestibular schwannoma 5. Sudden sensorineural hearing loss 7. History of Cerebrovascular disorders 8. History of ear operation other than myringotomy and tube placement in the past 9. Planned major surgery of the skull base (for instance, cochlear implant) 10. Systemic disorders to include chronic renal failure, cirrhosis of the liver, autoimmune disease, heart disease, lung disease, or severe arthritis 11. Individuals who cannot provide informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Otoband
The Otoband will be used by participants during migraine associated vertigo (MAV). We expect the research subjects to use the device for at least 20 minutes, with the hardware limiting any one session to a duration of 30 minutes, up to 4 times per calendar day. The Otoband will be set to the effective power level during the course of a given calendar day.
Otoband sham
The Otoband will be used by participants during migraine associated vertigo (MAV) for a maximum of 30 minutes, up to 4 times per calendar day. The Otoband will be set to an ineffective power level (considered a sham device) during the course of a given calendar day.

Locations

Country Name City State
United States Thomas Jefferson Hospital Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Otolith Labs

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in vertigo symptoms Questionnaire for vertigo symptoms from 0 (none) to 10 (agonizing) 2 minutes and 20 minutes after starting the Otoband; and 20 minutes after stopping the Otoband
Primary Brain confusion Questionnaire for brain confusion: scale from 0 (none) to 10 (maximum) for the 4 following symptoms: forgetful, difficulty thinking/finding words, difficulty focusing, cloudy. 2 minutes and 20 minutes after starting the Otoband; and 20 minutes after stopping the Otoband
Secondary Change in nausea symptoms Questionnaire for nausea symptoms from 0 (none) to 10 (agonizing) 2 minutes and 20 minutes after starting the Otoband; and 20 minutes after stopping the Otoband
Secondary Change in headache symptoms Questionnaire for nausea symptoms from 0 (none) to 10 (worst pain possible) 2 minutes and 20 minutes after starting the Otoband; and 20 minutes after stopping the Otoband
See also
  Status Clinical Trial Phase
Withdrawn NCT03472872 - A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache Phase 4
Withdrawn NCT05410366 - Safe Harbors in Emergency Medicine, Specific Aim 3
Withdrawn NCT02866084 - Neuromodulation Treatment of Vestibular Migraines N/A
Active, not recruiting NCT03537573 - Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care N/A
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Not yet recruiting NCT04352218 - Safety Profile of PETALO CVS in the Treatment of Non-thrombotic Internal Jugular Vein Stenosis and Chronic Headache Phase 2
Completed NCT02734992 - Acceptance and Commitment Therapy vs Medical Treatment as Usual Wait-list Control for Primary Headache Sufferers N/A
Completed NCT01153789 - Study of Oculomotor Dysfunction Leading to Children Vertigo N/A
Completed NCT01327118 - Prostaglandin F2alpha in a Human Headache Model N/A
Not yet recruiting NCT00969995 - Identification of Inflammatory Markers in Migraine Patients N/A
Not yet recruiting NCT00752921 - Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache Phase 4
Terminated NCT00291395 - PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers Phase 1
Completed NCT00212810 - Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache. Phase 4
Completed NCT00263094 - An End to the Yom Kippur (and Ramadan) Headache N/A
Completed NCT00135122 - Prednisolone in the Treatment of Withdrawal Headache in Probable Medication Overuse Headache Phase 3
Completed NCT02475005 - An Intervention to Improve Adolescent Headache Self-management N/A
Completed NCT03163901 - The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury N/A
Completed NCT01664585 - Exercise Training With Physically Active Lifestyle to Reduce Headache and Quality of Life N/A
Completed NCT04632420 - Evaluation of Headache and Childbirth in a Chronic Pain Population
Recruiting NCT05033613 - Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease